Unique perspectives
bold insights
Explore articles and perspectives from the brightest minds in investment and medical research.
Building the foundations for faster progress against brain cancer
Uniting researchers, clinicians and patients to accelerate research and improve patient care.
Understanding spinal cord injury recovery
The world's first molecular map of spinal cord injury across time and injury levels
Giving families living with rare diseases the answers they need
Supporting research to improve the diagnosis of rare genetic neuromuscular diseases and build the foundations for future treatments.
Understanding fatigue in young people with Charcot-Marie-Tooth disease
Developing a tool to improve understanding, research and care.
Improving care for adults with motor neuron diseases
Building better care for adults living with Motor Neuron Disease and Spinal Muscular Atrophy.
Improving the diagnosis of muscle disorders using advanced genetic testing
Focused on improving the efficiency and accuracy of diagnosing muscle disorders.
Targeting the drivers of cancer growth
Exploring how extrachromosomal DNA (ecDNA) drives cancer growth, spread and treatment resistance.
Protecting the heart when every minute matters
Investigating a new treatment to reduce heart damage after heart attacks
Harnessing the power of stem cell technology
Developing cell therapies for patients with blood diseases
The Future of Pain Management
Enhancing healthcare professionals' ability to deliver better pain management, now and into the future.
There are no bears in Taipei: what a research trip revealed about the AI infrastructure buildout
What happens when you spend two weeks meeting the companies building the AI revolution? CIO Nick Griffin and Investment Analyst Jean Huang share their biggest insights from Taiwan.
Solving the genetic causes of autoimmune diseases
Mapping hundreds of risk markers to better understand how these diseases develop and progress
Advancing treatment options for type 1 diabetes
Improving blood glucose and reducing insulin needs.
Revealing what drives PSP
Mapping the biological changes behind progressive supranuclear palsy in the brain.
Rethinking Osteoarthritis
Building new insights into one of Australia's most common and disabling conditions.
A new approach to Parkinson’s Disease
Exploring nerve stimulation as a potential treatment.
Unlocking the mysteries of the human brain
The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.
Revolutionising Diabetes Care
Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.
Next generation CAR T-cell therapy for cancer
The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.
Stock Spotlight | Puuilo
Puuilo is a Finnish retail chain known for its wide product range, affordable prices, convenient locations and easy shopping experience.
The changing world order and what it means for investors
Michael Allen, Managing Director and Partner at Beacon Global Strategies, chats to Alan Pullen of Magellan Investment Partners about the current geopolitical landscape.
Earnings season wrap-up: the structural changes driving markets
Munro Partners' Investment Analysts, Ben Chamberlain, Dan Condon and Nicky Sun unpack the key insights from Q1 2026 earnings season and what they mean for Munro's Areas of Interest.
‘No from us’: Antipodes avoids SpaceX but likes this AI stock instead
Vihari Ross talks about the market’s hottest IPO, where she’s spotting opportunity to ride the chip boom and why she cashed out of Hyundai.
Plato, Munro invest in SpaceX as rival funds wait for the sellers
“We love the company and, like any Elon company, it is unique and has amazing long-term opportunities, but the price is a little hard to stomach, so hopefully we get a better opportunity,” said Griffin.
Stock Spotlight | Contemporary Amperex Technology
Contemporary Amperex Technology (3750.HK) has recently been added to the HM1 portfolio, following a recommendation from Munro Partners.
Munro Partners’ Nick Griffin on picking the few winners and avoiding the losers in global equities
Nick explains why his team focuses on investing in structurally growing companies and the main characteristics to look for in identifying those that will be the long-term winners. Nick also shares his views on structural themes that are providing the tailwinds from which winners will emerge.
